Dolphin Medical Services Ltd Stock Price Today (NSE: DOLPHMED)

Dolphin Medical Services Ltd

7.14+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Dolphin Medical Services Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Dolphin Medical Services Ltd share price today is 7.14, up +0.00% on NSE/BSE as of 7 August 2026. Dolphin Medical Services Ltd (DOLPHMED) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of 12.50 (Cr). The 52-week high for DOLPHMED share price is 9.57 and the 52-week low is 1.98. At a P/E ratio of 312.50x, DOLPHMED is currently trading above its industry average P/E of 42.23x. The company has a Return on Equity (ROE) of 0.40% and a debt-to-equity ratio of 0.09.

Dolphin Medical Services Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
9.57
Low
7.14
Volume
65.6K
Change
-17.98%

Dolphin Medical Services Ltd share price chart: -17.98% return over the past month. 52-week high ₹9.57, 52-week low ₹1.98.

Dolphin Medical Services Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
7.147.147.147.140.00 (Cr)
7.147.147.147.140.00 (Cr)
7.857.857.127.141.23L (Cr)
7.487.487.487.480.00 (Cr)
7.487.487.487.480.00 (Cr)
7.487.487.487.480.00 (Cr)
7.488.267.487.482.62L (Cr)
7.877.877.877.870.00 (Cr)
7.877.877.877.870.00 (Cr)
7.877.877.877.870.00 (Cr)

Dolphin Medical Services Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
7.857.857.127.14-9.04%
9.129.577.487.48-17.98%
7.529.127.529.12+21.28%
6.207.176.057.17+15.65%
4.885.914.875.91+21.11%
3.834.883.644.88+27.42%
3.033.833.163.83+26.40%
2.933.282.743.17+8.19%
2.162.872.162.87+32.87%
2.042.271.992.27+11.27%
2.162.281.982.05-5.09%
2.262.372.012.16-4.42%

AI Research Briefing

Powered by Gemini · 2026-08-01

Brutal shell-takeover play with ₹0.75 Cr annual revenue trading at 312x P/E, strictly for speculative position-flipping around open offer headlines.

Research Confidence
4.5/10Low
OPERATOR-DRIVENConsolidation over 1M (0.0%), strong momentum over 3M (54.19%) and 6M (164.54%) driven by takeover filings.Extreme valuation stretch; trading at 312.5x P/E versus healthcare industry P/E of 42.23x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Promoters Gude Venkata Mohan Prasad and Lakshmi Sudha Madala executed a Share Purchase Agreement on May 15, 2026, selling a 20.95% stake (31,63,390 shares) to incoming acquirers Amarandhar Reddy Kotha and Mallour Rajesh Kumar. A mandatory open offer launched on July 31, 2026 (closing August 13, 2026) to acquire up to 26% additional voting capital (39,25,988 shares) from public shareholders at ₹4.80 per share. FY26 full-year sales fell 3.85% YoY to ₹0.75 Cr, though full-year net profit managed ₹0.04 Cr versus a ₹0.03 Cr loss in FY25.

CORE STORY (THE REAL GAME)

This is an operator-driven micro-cap reverse merger and shell-takeover play, not a fundamental healthcare growth story. With top-line revenue under ₹1 Cr annually, investors are betting entirely on incoming promoters injecting new assets or pivoting operations post-takeover.

Why Now
  • Open offer tendering period running from July 31 to August 13, 2026 at ₹4.80 per share
  • Promoter control shift to Amarandhar Reddy Kotha and Mallour Rajesh Kumar buying 20.95% stake via SPA
  • FY26 full-year results showing sales down 3.85% YoY to ₹0.75 Cr
Potential Catalysts
  • Completion of open offer and regulatory reclassification of new promoters
  • Post-takeover management announcement of new asset injection or business pivot
  • Q1 FY27 earnings showing actual revenue expansion beyond base diagnostic operations
Key Risks
  • Illiquid SME micro-cap (₹12.5 Cr market cap) with severe execution and exit risk
  • Negligible operating scale with FY26 revenue of just ₹0.75 Cr and negative 5-year FCF of ₹-0.59 Cr
  • Absurd 312.5x P/E valuation against an industry average of 42.2x
Institutional Activity

Zero institutional participation; FII and DII holdings both stand at 0.0% with zero change.

Macro Context

Indian diagnostic and healthcare sector consolidating rapidly, leaving micro-players without scale vulnerable to complete obsolescence.

Order Book / Expansion

No major order wins or commercial contracts reported; focus remains solely on the open offer control change.

Cash Flow Quality

Poor cash flow quality; 5-year cumulative free cash flow sits at negative ₹-0.59 Cr.

3–6 Month Outlook

Subdued core execution; performance over 3-6 months depends entirely on incoming promoters injecting fresh capital or new assets.

Primary Thesis Risk

Failure of incoming promoters to inject viable revenue-generating assets into a business generating under ₹1 Cr annually.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

0.40%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

0.64%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

-5.39%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Dolphin Medical Services Ltd Valuation Check

Poor

Price to Earnings (P/E)

312.50x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

42.23x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

26.44%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

114.29%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

35.71%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

9.80%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

16.32%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

16.32%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.09x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

7.00x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-0.59 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Dolphin Medical Services Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of DOLPHMED across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Robust Profit Growth (114.29%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (35.71%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Excellent EPS Growth (16.32% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (16.32% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.09)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (7.00x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

7 factors identified

Below-Average Return on Equity (0.40%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (0.64%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (-5.39%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Premium Valuation Risk (P/E: 312.50x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Negative Free Cash Flow (₹-0.59 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Low Promoter Commitment (26.44%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Dolphin Medical Services Ltd vs Healthcare Service Provider Peers

Peer Comparison - Healthcare Service Provider

Compare Dolphin Medical Services Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
33.4/100
7
₹12.50
312.5
Average
0.40%
Poor
0.64%
Poor
0.1
Excellent
16.32%
Excellent
9.80%
Good
0.00%
57.7/100
1905
₹28908.91
55.4
Average
22.30%
Excellent
28.00%
Excellent
0.1
Excellent
12.33%
Good
11.81%
Good
0.81%
67.8/100
1344
₹14307.85
82.7
Average
19.74%
Good
21.29%
Excellent
0.4
Excellent
15.47%
Excellent
16.66%
Excellent
0.14%
57.9/100
582
₹11858.49
60.4
Average
13.81%
Average
17.77%
Good
0.1
Excellent
1.46%
Average
10.52%
Good
0.35%
46.7/100
579
₹8420.27
52.4
Average
28.40%
Excellent
35.38%
Excellent
0.1
Excellent
8.37%
Good
10.88%
Good
1.76%
31.9/100
527
₹1777.47
17.3
Average
10.89%
Average
12.70%
Average
0.5
Good
-11.13%
Poor
11.75%
Good
0.50%
56.2/100
252
₹1359.30
42.2
Average
14.12%
Average
16.97%
Good
0.5
Good
31.68%
Excellent
17.26%
Excellent
0.00%
82.2/100
565
₹1178.25
16.9
Average
65.27%
Excellent
87.02%
Excellent
0.0
Excellent
97.21%
Excellent
167.02%
Excellent
0.00%
60.3/100
1248
₹1079.13
18.4
Average
19.77%
Good
25.48%
Excellent
0.0
Excellent
-12.44%
Poor
-8.95%
Poor
0.31%
39/100
301
₹1035.54
539.3
Average
0.29%
Poor
-0.05%
Poor
0.0
Excellent
16.91%
Excellent
19.09%
Excellent
0.00%
49.4/100
239
₹600.78
20.6
Average
19.92%
Good
23.27%
Excellent
0.3
Excellent
0.00%

Dolphin Medical Services Ltd Quarterly Performance

Latest quarterly metrics for DOLPHMED — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

35.71%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

114.29%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

9.80%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

16.32%

Compounded annual net profit growth over 5 years

Dolphin Medical Services Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for DOLPHMED — calculated from daily price history

0RSI 14
Oversold — RSI 0

Selling pressure is heavy — potential reversal zone.

SMA 50
8
▼ Price below SMA 50 — Short-term bearish
30-Day Avg Volume
52K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Dolphin Medical Services Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Dolphin Medical Services Ltd (DOLPHMED) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Dolphin Medical Services Ltd

About DOLPHMED (Dolphin Medical Services Ltd)

Dolphin Medical Services Ltd is a prominent healthcare provider committed to delivering comprehensive and advanced medical solutions within the region. With a focus on patient-cent...ric care, DOLPHMED offers a wide spectrum of diagnostic services, including cutting-edge imaging technologies, laboratory testing, and specialized health screenings. We pride ourselves on employing a team of highly qualified and experienced medical professionals who are dedicated to accuracy, efficiency, and personalized attention for every individual. DOLPHMED aims to be a trusted partner in promoting health and well-being within the community by continuously investing in innovative technologies and upholding the highest standards of quality and ethics in the healthcare industry. At Dolphin Medical Services Ltd, we understand the critical role of timely and accurate diagnoses in ensuring positive patient outcomes. Therefore, we are dedicated to providing state-of-the-art diagnostic facilities equipped with the latest medical equipment. Our team of skilled technicians and radiologists work in tandem to deliver precise and detailed results, enabling doctors to make informed decisions about treatment plans. Furthermore, DOLPHMED emphasizes a comfortable and supportive environment for patients undergoing various diagnostic procedures, ensuring their comfort and minimizing anxiety. We are committed to maintaining confidentiality and adhering to strict protocols to safeguard patient information. DOLPHMED is deeply rooted in its commitment to the local community, striving to be a valuable resource for individuals seeking accessible and reliable healthcare services. Through collaborations with local hospitals, clinics, and healthcare professionals, we aim to expand our reach and improve access to essential diagnostic services. We actively participate in health awareness programs and initiatives, promoting preventive care and empowering individuals to take control of their health. Dolphin Medical Services Ltd aspires to be a pillar of support in the community, fostering a healthier and more vibrant society by delivering superior healthcare solutions with compassion and integrity.

Company Details

Symbol:DOLPHMED
Industry:Healthcare Service Provider
Sector:Healthcare Service Provider

Key Leadership

Dr. Venkata Mohan Prasad Gude
CEO, MD & Executive Director
Dr. Lakshmi Sudha Madala
CFO, Compliance Officer & Whole-Time Director
Mr. Nanapaneni Buddha Sagar
Executive Director

DOLPHMED Share Price: Frequently Asked Questions

What is the current share price of Dolphin Medical Services Ltd?

Dolphin Medical Services Ltd (DOLPHMED) trades at ₹7.14 on NSE and BSE. Market cap ₹12.50 (Cr). Educational data only.

What is the P/E ratio of Dolphin Medical Services Ltd?

Dolphin Medical Services Ltd has a P/E of 312.50x vs industry average 42.23x.

What is the Bull Run score for Dolphin Medical Services Ltd?

Dolphin Medical Services Ltd has a Bull Run score of 33.4/100 based on 25+ financial parameters.

Does Dolphin Medical Services Ltd pay dividends?

Dolphin Medical Services Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Dolphin Medical Services Ltd?

Dolphin Medical Services Ltd has ROE of 0.40%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Dolphin Medical Services Ltd?

Dolphin Medical Services Ltd has debt-to-equity of 0.09.

Is Dolphin Medical Services Ltd a good investment?

Bull Run gives Dolphin Medical Services Ltd a score of 33.4/100. This is not investment advice — consult a SEBI-registered advisor.